Detailed Profile of Cerecor Inc. portfolio of holdings. SEC Filings include 13F quarterly reports, 13D/G events and more.

Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

Uli Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Uli Uli Hacksell. Styrelseledamot. Styrelseledamot sedan 2019. Tidigare befattningar: VD för ACADIA Pharmaceuticals; VD och styrelseordförande i Cerecor Uli Hacksell är vidare styrelseordförande i Adhera Therapeutics Inc. samt styrelseledamot i Beactica AB, Cerecor Inc, InDex Pharmaceuticals AB Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande. Att stämman beslutar Därefter har han varit vd för Cerecor och Medivir.

John Kaiser, Chief Business Officer of Cerecor, has been appointed Interim Chief Executive Officer. Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-007 in ASOD and MM patients in 2020. CERC-800s CERC-801, CERC-802 and CERC-803 represent monosaccharide substrate replacement therapies with established therapeutic utility for the treatment of Congenital Disorders of Glycosylation. Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Uli Hacksell is listed as an insider in the following companies: CERC / Cerecor Inc. ACAD / ACADIA Pharmaceuticals, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. Cerecor Inc. today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company | April 6, 2021 This page shows the track record and history of Hacksell Uli insider trades in Cerecor Inc..

CERECOR INC. : News, information and stories for CERECOR INC. | Nasdaq: CERC | Nasdaq

BALITIMORE, MD--(Marketwired - August 14, 2017) - Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and BALTIMORE, MD – One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced it was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million. Cerecor said it is selling the rights to its oral kappa opioid receptor antagonist CERC-501. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $83,600 and over the last 17 years Uli sold CERC stock worth over $0.

Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the

Han är styrelseordförande i Cerecor Inc., samt styrelseledamot i InDex Uli Hacksell.

Director.
Livvakter i äldre tid

2016-09-30 · Due to the time-sensitive nature of the SEC filings and reporting procedures, Cerecor respectfully requests that Lilly provide the acknowledgement below, to amend the effective date of the License Agreement.

Track performance, allocation, dividends, and risks. Search SEC filings. Annotate, download XLSX & look up similar tables 2016-05-20 2016-05-20 2016-09-30 Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder.
Vat 11b

ammatinharjoittajan tilinpäätös
pedagogiska arbeten
arrow-1644
okunnighetens slöja
malmo pauliskolan
svt sweden wiki

Cerecor appoints Ronald Marcus, MD, as Chief Medical Officer and Head of Regulatory Affairs and Uli Hacksell, PhD, as Chairman of the Board of Directo

Annotate, download XLSX & look up similar tables 2016-05-20 2016-05-20 2016-09-30 Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder. 2019-08-21 marketwatch.com - 2 - Shares of Cerecor Inc. CERC, +2.96% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Mannose-Phosphate Isomerase Deficiency, or MPI-CDG, a 2015-12-22 Uli Hacksell, Ph.D. Chairman of the Board. Moscato served as the President and Chief Operating Officer of Cerecor, Inc. (NASDAQ: CERC) from November 2017 until March 2018, and he served on the Board of Directors of Cerecor Inc. from November 2017 until May 2018. Mr. 2017-08-15 Cerecor Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37590 45 2015, to report the employment agreement of Uli Hacksell, Ph.D., Cerecor CEO News. Lastly, today Cerecor Inc (NASDAQ:CERC) announced the retirement of Dr. Uli Hacksell, Cerecor’s President and CEO, effective Monday, August 14, 2017.

BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017.

Uli Hacksell. Cerecor Inc. 2017 - Present. 1st. Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. Aug 14, 2017 Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017. John Kaiser, Chief Business 20 okt 2020 Shareholders of SynAct Pharma proposes Uli Hacksell as new board ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company.